WAVE LIFE SCIENCES LTD. Revenue
WAVE LIFE SCIENCES LTD. (WVE) reported Revenue of $2.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-30
- WAVE LIFE SCIENCES LTD. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $2.27M, a 73.88% decline year-over-year.
- WAVE LIFE SCIENCES LTD. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $38.25M, a 316.85% increase year-over-year.
- WAVE LIFE SCIENCES LTD. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $8.70M, a 55.82% decline year-over-year.
- WAVE LIFE SCIENCES LTD. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $9.18M, a 26.82% decline year-over-year.
- WAVE LIFE SCIENCES LTD. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $42.73M, a 60.55% decline from fiscal 2024.
- WAVE LIFE SCIENCES LTD. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $108.30M, a 4.42% decline from fiscal 2023.
- WAVE LIFE SCIENCES LTD. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $113.31M, a 3005.10% increase from fiscal 2022.
- WAVE LIFE SCIENCES LTD. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $3.65M, a 91.09% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.27M 10-Q · filed 2026-07-30 | $40.52M 10-Q · filed 2026-07-30 | ||
| 2026-03-31 | $38.25M 10-Q · filed 2026-04-28 | |||
| 2025-12-31 | $42.73M 10-K · filed 2026-02-26 | |||
| 2025-06-30 | $8.70M 10-Q · filed 2026-07-30 | $17.87M 10-Q · filed 2026-07-30 | ||
| 2025-03-31 | $9.18M 10-Q · filed 2026-04-28 | |||
| 2024-12-31 | $108.30M 10-K · filed 2026-02-26 | |||
| 2024-06-30 | $19.69M 10-Q · filed 2025-07-30 | $32.23M 10-Q · filed 2025-07-30 | $61.29M derived: sum of 3 quarters · filed 2026-02-26 | $110.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $12.54M 10-Q · filed 2025-05-08 | $41.59M derived: sum of 2 quarters · filed 2026-02-26 | $90.81M derived: sum of 3 quarters · filed 2026-02-26 | $112.91M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $29.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $78.27M derived: sum of 2 quarters · filed 2026-02-26 | $100.38M derived: sum of 3 quarters · filed 2026-02-26 | $113.31M 10-K · filed 2026-02-26 |
| 2023-09-30 | $49.21M 10-Q · filed 2023-11-09 | $71.32M derived: sum of 2 quarters · filed 2024-08-08 | $84.25M 10-Q · filed 2023-11-09 | $85.49M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $22.11M 10-Q · filed 2024-08-08 | $35.03M 10-Q · filed 2024-08-08 | $36.27M derived: sum of 3 quarters · filed 2025-03-04 | $36.56M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | $12.93M 10-Q · filed 2024-05-10 | $14.17M derived: sum of 2 quarters · filed 2025-03-04 | $14.45M derived: sum of 3 quarters · filed 2025-03-04 | $14.83M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $1.52M derived: sum of 2 quarters · filed 2025-03-04 | $1.90M derived: sum of 3 quarters · filed 2025-03-04 | $3.65M 10-K · filed 2025-03-04 |
| 2022-09-30 | $285.00K 10-Q · filed 2023-11-09 | $660.00K derived: sum of 2 quarters · filed 2023-11-09 | $2.41M 10-Q · filed 2023-11-09 | $4.17M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $375.00K 10-Q · filed 2023-08-03 | $2.13M 10-Q · filed 2023-08-03 | $3.89M derived: sum of 3 quarters · filed 2023-08-03 | $40.31M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $1.75M 10-Q · filed 2023-05-03 | $3.52M derived: sum of 2 quarters · filed 2023-05-03 | $39.94M derived: sum of 3 quarters · filed 2023-05-03 | $42.71M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $38.19M derived: sum of 2 quarters · filed 2023-03-23 | $40.96M derived: sum of 3 quarters · filed 2023-03-23 | $40.96M 10-K · filed 2023-03-23 |
| 2021-09-30 | $36.42M 10-Q · filed 2022-11-10 | $39.20M derived: sum of 2 quarters · filed 2022-11-10 | $39.20M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $2.78M 10-Q · filed 2022-08-11 | $2.78M 10-Q · filed 2022-08-11 | ||
| 2020-12-31 | $9.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $12.89M derived: sum of 2 quarters · filed 2022-03-03 | $15.92M derived: sum of 3 quarters · filed 2022-03-03 | $20.08M 10-K · filed 2022-03-03 |
| 2020-09-30 | $3.45M 10-Q · filed 2021-11-10 | $6.48M derived: sum of 2 quarters · filed 2021-11-10 | $10.64M 10-Q · filed 2021-11-10 | $13.04M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $3.03M 10-Q · filed 2021-08-05 | $7.19M 10-Q · filed 2021-08-05 | $9.59M derived: sum of 3 quarters · filed 2021-08-05 | $12.52M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $4.16M 10-Q · filed 2021-05-13 | $6.56M derived: sum of 2 quarters · filed 2021-05-13 | $9.49M derived: sum of 3 quarters · filed 2021-05-13 | $17.12M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $2.40M 10-K · filed 2020-03-02 | $5.33M derived: sum of 2 quarters · filed 2020-11-09 | $12.96M derived: sum of 3 quarters · filed 2020-11-09 | $15.98M 10-K · filed 2021-03-04 |
| 2019-09-30 | $2.93M 10-Q · filed 2020-11-09 | $10.56M derived: sum of 2 quarters · filed 2020-11-09 | $13.58M 10-Q · filed 2020-11-09 | $17.20M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $7.63M 10-Q · filed 2020-08-10 | $10.65M 10-Q · filed 2020-08-10 | $14.27M derived: sum of 3 quarters · filed 2020-08-10 | $18.77M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $3.03M 10-Q · filed 2020-05-11 | $6.65M derived: sum of 2 quarters · filed 2020-05-11 | $11.14M derived: sum of 3 quarters · filed 2020-05-11 | $16.02M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $3.62M 10-K · filed 2020-03-02 | $8.11M derived: sum of 2 quarters · filed 2020-03-02 | $12.99M derived: sum of 3 quarters · filed 2020-03-02 | $14.41M 10-K · filed 2020-03-02 |
| 2018-09-30 | $4.49M 10-K · filed 2020-03-02 | $9.37M derived: sum of 2 quarters · filed 2020-03-02 | $10.79M 10-Q · filed 2019-11-05 | $11.89M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $4.88M 10-K · filed 2020-03-02 | $6.30M 10-Q · filed 2019-08-06 | $7.40M derived: sum of 3 quarters · filed 2020-03-02 | $8.71M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $1.42M 10-K · filed 2020-03-02 | $2.52M derived: sum of 2 quarters · filed 2020-03-02 | $3.83M derived: sum of 3 quarters · filed 2020-03-02 | $4.93M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $1.10M 10-K · filed 2019-03-01 | $2.41M derived: sum of 2 quarters · filed 2019-03-01 | $3.51M derived: sum of 3 quarters · filed 2019-03-01 | $3.89M 10-K · filed 2020-03-02 |
| 2017-09-30 | $1.31M 10-K · filed 2019-03-01 | $2.41M derived: sum of 2 quarters · filed 2019-03-01 | $2.79M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $1.10M 10-K · filed 2019-03-01 | $1.48M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $383.00K 10-K · filed 2019-03-01 | |||
| 2016-12-31 | $1.09M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |